Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinephrine and Cortisol Effects on Emotion in Depression
NCT04148261Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of hydrocortisone in major depressive disorder (MDD) (4 arms), sponsored by Stanford University. Primary endpoint: Sadness-induced subgenual cingulate activity at 2 hours. Planned start Dec 2020; status: withdrawn.
02
Drugs
hydrocortisone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04148261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148261.